Amyloidosis is a rare, multisystem disease that leads to deposition of misfolded proteins in various organs. This case report ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...

Eplontersen is recommended, within its marketing authorisation, as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy. It is only ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

There is a simple discount patient access scheme for eplontersen. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact Market.AccessUK ...

The prognosis of patients with cardiac amyloidosis is affected by their cardiac condition, the extracardiac involvement and the modality of treatment of the underlying disease. Another predictor ...

Previously known as primary amyloidosis, systemic amyloid light chain (AL) amyloidosis is the most common form of systemic amyloidosis in developed countries. Although occasionally localized and ...

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a buy rating to a hold rating in a ...

PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...